Differences and similarities between mesenchymal stem cell and endothelial progenitor cell immunoregulatory properties against T cells  

作　　者：Mehdi Razazian Maryam Khosravi Sheyda Bahiraii Georges Uzan Sara Shamdani Sina Naserian 

机构地区：[1]Institut national de la santéet de la recherche médicale(Inserm)UnitéMixte de Recherche-Inserm-Ministère de la Défense 1197,Hôpital Paul Brousse,Villejuif 94800,France [2]Microenvironment&Immunity Unit,Institut Pasteur,Paris 75724,France [3]Institut national de la santéet de la recherche médicale(Inserm)Unit 1224,Paris 75724,France [4]Department of Pharmacognosy,University of Vienna,Vienna 1090,Austria [5]Paris-Saclay University,Villejuif 94800,France [6]CellMedEx,Saint Maur Des Fossés 94100,France

出　　处：《World Journal of Stem Cells》2021年第8期971-984,共14页世界干细胞杂志（英文版）（电子版）

摘　　要：Bone-marrow-derived mesenchymal stem cells and endothelial progenitor cells have some interesting biological properties that make them unique for cell therapy of degenerative and cardiovascular disorders.Although both cell populations have been already studied and used for their regenerative potentials,recently their special immunoregulatory features have brought much more attention.Mesenchymal stem cells and endothelial progenitor cells have both proangiogenic functions and have been shown to suppress the immune response,particularly T cell proliferation,activation,and cytokine production.This makes them suitable choices for allogeneic stem cell transplantation.Nevertheless,these two cells do not have equal immunoregulatory activities.Many elements including their extraction sources,age/passage,expression of different markers,secretion of bioactive mediators,and some others could change the efficiency of their immunosuppressive function.However,to our knowledge,no publication has yet compared mesenchymal stem cells and endothelial progenitor cells for their immunological interaction with T cells.This review aims to specifically compare the immunoregulatory effect of these two populations including their T cell suppression,deactivation,cytokine production,and regulatory T cells induction capacities.Moreover,it evaluates the implications of the tumor necrosis factor alpha-tumor necrosis factor receptor 2 axis as an emerging immune checkpoint signaling pathway controlling most of their immunological properties.

关 键 词：Endothelial Progenitor Cells Mesenchymal Stem Cells T cells IMMUNOSUPPRESSION IMMUNOREGULATION TNFα-TNFR2 signaling pathway 

分 类 号：R392[医药卫生—免疫学]